Clinical Trial Update: Modified Vaccinia Ankara (MVA) Vaccine Study [Phase 1]

View source ↗

Summary

A Phase 1 study of a Modified Vaccinia Ankara (MVA) vaccine for nasopharyngeal carcinoma and Epstein-Barr virus infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Nasopharyngeal Carcinoma

Drugs mentioned

• Modified Vaccinia Ankara (MVA) vaccine (Modified Vaccinia Ankara (MVA) vaccine)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections | Phase 1 | Status: COMPLETED